Search Grant Opportunities

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2

ID: RFA-DA-28-001 • Type: Forecasted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Analyze Opportunity
Generate a Draft
Loading

Description

NIDA seeks to further advance its mission in the area of single cell biology. Since 2020, the NIDA-funded Single Cell Opioid Responses in the Context of HIV (SCORCH) consortium has generated single-nucleus datasets from human and animal postmortem brain tissue under conditions of HIV infection, antiretroviral therapy (ART), and/or substance exposure (e.g. opioids, cocaine, methamphetamine, and cannabinoids). Building on this Phase 1 foundation, NIDA will encourage research addressing critical questions on Substance Use Disorder (SUD) and interactions with HIV disease progression at the subcellular, cellular, or circuit levels in the Central Nervous System (CNS). Many new cutting-edge single cell approaches (e.g. interrogation of RNA splicing, non-coding RNAs, epigenomic or proteomic features, subcellular or synaptic localization and function, spatial interactions, cell-cell communication, or cellular connectivity) now enable novel hypothesis-generating studies. Along with data mining studies to identify candidate mechanisms or targets contributing to HIV/SUD interactions and hypothesis-driven studies to assess functional significance, we expect SCORCH Phase 2 to significantly advance our mechanistic understanding of SUDs and HIV in the CNS and identify targets for novel therapies. Grant authorities that allow NIDA to forecast this opportunity are 42 U.S.C. 241 and 284

NIDA seeks to further advance its mission in the area of single cell biology. Since 2020, the NIDA-funded Single Cell Opioid Responses in the Context of HIV (SCORCH) consortium has generated single-nucleus datasets from human and animal postmortem brain tissue under conditions of HIV infection, antiretroviral therapy (ART), and/or substance exposure (e.g. opioids, cocaine, methamphetamine, and cannabinoids). Building on this Phase 1 foundation, NIDA will encourage research addressing critical questions on Substance Use Disorder (SUD) and interactions with HIV disease progression at the subcellular, cellular, or circuit levels in the Central Nervous System (CNS). Many new cutting-edge single cell approaches (e.g. interrogation of RNA splicing, non-coding RNAs, epigenomic or proteomic features, subcellular or synaptic localization and function, spatial interactions, cell-cell communication, or cellular connectivity) now enable novel hypothesis-generating studies. Along with data mining studies to identify candidate mechanisms or targets contributing to HIV/SUD interactions and hypothesis-driven studies to assess functional significance, we expect SCORCH Phase 2 to significantly advance our mechanistic understanding of SUDs and HIV in the CNS and identify targets for novel therapies. Grant authorities that allow NIDA to forecast this opportunity are 42 U.S.C. 241 and 284

Overview

Category of Funding
Health
Funding Instruments
Cooperative Agreement
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 8/20/26 the National Institutes of Health forecasted grant opportunity RFA-DA-28-001 for Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2 with funding of $5.0 million. The grant will be issued under grant program 93.279 Drug Abuse and Addiction Research Programs. It is expected that 8 total grants will be made.

Timing

Forecast Posted Date
Est. Application Posting Date
Est. Synopsis Response Date
Forecasted
Last Updated
Version
1

Eligibility

Eligible Applicants
For profit organizations other than small businesses
Native American tribal governments (Federally recognized)
State governments
County governments
City or township governments
Public housing authorities/Indian housing authorities
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Special district governments
Independent school districts
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Public and State controlled institutions of higher education
Small businesses
Additional Info
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;

Award Sizing

Ceiling
$1,000,000
Floor
Not Listed
Estimated Program Funding
$5,000,000
Estimated Number of Grants
8

Contacts

Contact
National Institute on Drug Abuse (NIDA)
Email Description
Inbox for NIDA Genetics, Epigenetics, and Development Branch Program Staff

Documents

Posted documents for RFA-DA-28-001

Opportunity Assistant


Analyze Opportunity

Generate a Draft

Potential Applicants and Partners

Awardees that have recently won grants similar to RFA-DA-28-001

Incumbent or Similar Grants

Grants similar to RFA-DA-28-001

Similar Active Opportunities

Open grant opportunities similar to RFA-DA-28-001

Experts for Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2

Recommended subject matter experts available for hire